nach oben

16.05.2024 | RESEARCH

Prognostic model incorporating immune checkpoint genes to predict the immunotherapy efficacy for lung adenocarcinoma: a cohort study integrating machine learning algorithms

verfasst von: Xi-Lin Yang, Zheng Zeng, Chen Wang, Guang-Yu Wang, Fu-Quan Zhang

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to develop and validate a nomogram based on immune checkpoint genes (ICGs) for predicting prognosis and immune checkpoint blockade (ICB) efficacy in lung adenocarcinoma (LUAD) patients. A total of 385 LUAD patients from the TCGA database and 269 LUAD patients in the combined dataset (GSE41272 + GSE50081) were divided into training and validation cohorts, respectively. Three different machine learning algorithms including random forest (RF), least absolute shrinkage and selection operator (LASSO) logistic regression analysis, and support vector machine (SVM) were employed to select the predictive markers from 82 ICGs to construct the prognostic nomogram. The X-tile software was used to stratify patients into high- and low-risk subgroups based on the nomogram-derived risk scores. Differences in functional enrichment and immune infiltration between the two subgroups were assessed using gene set variation analysis (GSVA) and various algorithms. Additionally, three lung cancer cohorts receiving ICB therapy were utilized to evaluate the ability of the model to predict ICB efficacy in the real world. Five ICGs were identified as predictive markers across all three machine learning algorithms, leading to the construction of a nomogram with strong potential for prognosis prediction in both the training and validation cohorts (all AUC values close to 0.800). The patients were divided into high- (risk score ≥ 185.0) and low-risk subgroups (risk score < 185.0). Compared to the high-risk subgroup, the low-risk subgroup exhibited enrichment in immune activation pathways and increased infiltration of activated immune cells, such as CD8 + T cells and M1 macrophages (P < 0.05). Furthermore, the low-risk subgroup had a greater likelihood of benefiting from ICB therapy and longer progression-free survival (PFS) than did the high-risk subgroup (P < 0.05) in the two cohorts receiving ICB therapy. A nomogram based on ICGs was constructed and validated to aid in predicting prognosis and ICB treatment efficacy in LUAD patients.

Nur mit Berechtigung zugänglich

Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535–54. https://doi.org/10.1016/S0140-6736(21)00312-3.CrossRefPubMed

Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198(6):897–907. https://doi.org/10.1007/s00408-020-00407-5.CrossRefPubMedPubMedCentral

Guerreiro T, Mayer A, Aguiar P, Araújo A, Nunes C. The effect of timeliness of care on lung cancer survival - a population-based approach. Ann Glob Health. 2023;89(1):39. https://doi.org/10.5334/aogh.3845.CrossRefPubMedPubMedCentral

Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–40. https://doi.org/10.1016/j.mayocp.2019.01.013.CrossRefPubMed

Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31. https://doi.org/10.1056/NEJMoa191023.CrossRefPubMed

Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–39. https://doi.org/10.1056/NEJMoa1917346.CrossRefPubMed

Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021;39(21):2339–49. https://doi.org/10.1200/JCO.21.00174.CrossRefPubMedPubMedCentral

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50. https://doi.org/10.1038/s41568-019-0116-x.CrossRefPubMedPubMedCentral

Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661–74. https://doi.org/10.1016/j.csbj.2019.03.006.CrossRefPubMedPubMedCentral

10.

Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–22. https://doi.org/10.1080/21645515.2019.1571892.CrossRefPubMedPubMedCentral

11.

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. https://doi.org/10.1186/s12943-019-1091-2.CrossRefPubMedPubMedCentral

12.

Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80–96. https://doi.org/10.1111/imr.12519.CrossRefPubMedPubMedCentral

13.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. https://doi.org/10.1038/nrc3239.CrossRefPubMedPubMedCentral

14.

Bacchelli C, Williams HJ. Opportunities and technical challenges in next-generation sequencing for diagnosis of rare pediatric diseases. Expert Rev Mol Diagn. 2016;16(10):1073–82. https://doi.org/10.1080/14737159.2016.1222906.CrossRefPubMed

15.

Choi RY, Coyner AS, Kalpathy-Cramer J, Chiang MF, Campbell JP. Introduction to machine learning, neural networks, and deep learning. Transl Vis Sci Technol. 2020;9(2):14. https://doi.org/10.1167/tvst.9.2.14.CrossRefPubMedPubMedCentral

16.

Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2022;23(1):40–55. https://doi.org/10.1038/s41580-021-00407-0.CrossRefPubMed

17.

Ling B, Ye G, Zhao Q, Jiang Y, Liang L, Tang Q. Identification of an immunologic signature of lung adenocarcinomas based on genome-wide immune expression profiles. Front Mol Biosci. 2021;7:603701. https://doi.org/10.3389/fmolb.2020.603701.CrossRefPubMedPubMedCentral

18.

Jia R, Sui Z, Zhang H, Yu Z. Identification and validation of immune-related gene signature for predicting lymph node metastasis and prognosis in lung adenocarcinoma. Front Mol Biosci. 2021;8:679031. https://doi.org/10.3389/fmolb.2021.679031.CrossRefPubMedPubMedCentral

19.

Hua L, Wu J, Ge J, et al. Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes. Front Cell Dev Biol. 2023;11:1060086. https://doi.org/10.3389/fcell.2023.1060086.CrossRefPubMedPubMedCentral

20.

Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882–3. https://doi.org/10.1093/bioinformatics/bts034.CrossRefPubMedPubMedCentral

21.

Xu D, Liu X, Wang Y, et al. Identification of immune subtypes and prognosis of hepatocellular carcinoma based on immune checkpoint gene expression profile. Biomed Pharmacother. 2020;126:109903. https://doi.org/10.1016/j.biopha.2020.109903.CrossRefPubMed

22.

Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011;132(3):315–25. https://doi.org/10.1111/j.1365-2567.2010.03398.x.CrossRefPubMedPubMedCentral

23.

Afrache H, Gouret P, Ainouche S, Pontarotti P, Olive D. The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response. Immunogenetics. 2012;64(11):781–94. https://doi.org/10.1007/s00251-012-0619-z.CrossRefPubMed

24.

Cheung-Lee WL, Link AJ. Genome mining for lasso peptides: past, present, and future. J Ind Microbiol Biotechnol. 2019;46(9–10):1371–9. https://doi.org/10.1007/s10295-019-02197-z.CrossRefPubMed

25.

Wang H, Yang F, Luo Z. An experimental study of the intrinsic stability of random forest variable importance measures. BMC Bioinformatics. 2016;17:60. https://doi.org/10.1186/s12859-016-0900-5.CrossRefPubMedPubMedCentral

26.

Huang S, Cai N, Pacheco PP, Narrandes S, Wang Y, Xu W. Applications of support vector machine (SVM) learning in cancer genomics. Cancer Genomics Proteomics. 2018;15(1):41–51. https://doi.org/10.21873/cgp.20063.CrossRefPubMed

27.

Zuo Z, Zhang G, Song P, et al. Survival nomogram for stage IB non-small-cell lung cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol. 2021;28(7):3941–50. https://doi.org/10.1245/s10434-020-09362-0.CrossRefPubMed

28.

Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9. https://doi.org/10.1158/1078-0432.CCR-04-0713.CrossRefPubMed

29.

Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. https://doi.org/10.1186/1471-2105-14-7.CrossRefPubMedPubMedCentral

30.

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–25. https://doi.org/10.1016/j.cels.2015.12.004.CrossRefPubMedPubMedCentral

31.

Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. https://doi.org/10.1073/pnas.0506580102.CrossRefPubMedPubMedCentral

32.

Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017;6:e26476. https://doi.org/10.7554/eLife.26476.CrossRefPubMedPubMedCentral

33.

Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. https://doi.org/10.1186/s13059-017-1349-1.CrossRefPubMedPubMedCentral

34.

Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression [published correction appears in Genome Biol. 2016 Dec 1;17 (1):249]. Genome Biol. 2016;17(1):218. https://doi.org/10.1186/s13059-016-1070-5.CrossRefPubMedPubMedCentral

35.

Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https://doi.org/10.1038/ncomms3612.CrossRefPubMed

36.

Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7. https://doi.org/10.1038/nmeth.3337.CrossRefPubMedPubMedCentral

37.

Yi M, Nissley DV, McCormick F, Stephens RM. ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications. Sci Rep. 2020;10(1):10258. https://doi.org/10.1038/s41598-020-66986-8.CrossRefPubMedPubMedCentral

38.

Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–14. https://doi.org/10.1093/nar/gkaa407.CrossRefPubMedPubMedCentral

39.

Finotello F, Mayer C, Plattner C, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11(1):34. https://doi.org/10.1186/s13073-019-0638-6.CrossRefPubMedPubMedCentral

40.

Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8. https://doi.org/10.1038/s41591-018-0136-1.CrossRefPubMedPubMedCentral

41.

Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. https://doi.org/10.1056/NEJMoa1709937.CrossRefPubMed

42.

Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85. https://doi.org/10.1056/NEJMoa2202170.CrossRefPubMedPubMedCentral

43.

Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389(6):491–503. https://doi.org/10.1056/NEJMoa2302983.

44.

Sica GL, Choi IH, Zhu G, et al. B7–H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18(6):849–61. https://doi.org/10.1016/s1074-7613(03)00152-3.CrossRefPubMed

45.

Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med. 2011;208(8):1683–94. https://doi.org/10.1084/jem.20100639.CrossRefPubMedPubMedCentral

46.

Bhatt RS, Berjis A, Konge JC, et al. KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1. Cancer Immunol Res. 2021;9(2):156–69. https://doi.org/10.1158/2326-6066.CIR-20-0315.CrossRefPubMed

47.

Leaton LA, Shortt J, Kichula KM, et al. Conservation, extensive heterozygosity, and convergence of signaling potential all indicate a critical role for KIR3DL3 in higher primates. Front Immunol. 2019;10:24. https://doi.org/10.3389/fimmu.2019.00024.CrossRefPubMedPubMedCentral

48.

Guillamón CF, Martínez-Sánchez MV, Gimeno L, et al. Activating KIRs on educated NK cells support downregulation of CD226 and inefficient tumor immunosurveillance. Cancer Immunol Res. 2019;7(8):1307–17. https://doi.org/10.1158/2326-6066.CIR-18-0847.CrossRefPubMed

49.

Schaafsma E, Fugle CM, Wang X, Cheng C. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. Br J Cancer. 2021;125(3):422–32. https://doi.org/10.1038/s41416-021-01400-2.CrossRefPubMedPubMedCentral

50.

Hesse C, Ginter W, Förg T, et al. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity. Eur J Immunol. 2013;43(10):2543–53. https://doi.org/10.1002/eji.201343429.CrossRefPubMed

51.

Paludan SR. Activation and regulation of DNA-driven immune responses. Microbiol Mol Biol Rev. 2015;79(2):225–41. https://doi.org/10.1128/MMBR.00061-14.CrossRefPubMedPubMedCentral

52.

Bednarski JJ, Sleckman BP. At the intersection of DNA damage and immune responses. Nat Rev Immunol. 2019;19(4):231–42. https://doi.org/10.1038/s41577-019-0135-6.CrossRefPubMedPubMedCentral

Titel: Prognostic model incorporating immune checkpoint genes to predict the immunotherapy efficacy for lung adenocarcinoma: a cohort study integrating machine learning algorithms
verfasst von: Xi-Lin Yang
Zheng Zeng
Chen Wang
Guang-Yu Wang
Fu-Quan Zhang
Publikationsdatum: 16.05.2024
Verlag: Springer US
Erschienen in: Immunologic Research
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-024-09492-7

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Prognostic model incorporating immune checkpoint genes to predict the immunotherapy efficacy for lung adenocarcinoma: a cohort study integrating machine learning algorithms

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO